Compare LZM & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LZM | LXEO |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Isle of Man | United States |
| Employees | 93 | N/A |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.6M | 418.9M |
| IPO Year | N/A | 2023 |
| Metric | LZM | LXEO |
|---|---|---|
| Price | $4.83 | $5.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 849.4K | 805.3K |
| Earning Date | 03-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $86.37 | N/A |
| Revenue Next Year | $202.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $2.43 |
| 52 Week High | $6.40 | $10.99 |
| Indicator | LZM | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 41.30 |
| Support Level | $3.83 | $4.95 |
| Resistance Level | $6.15 | $6.08 |
| Average True Range (ATR) | 0.42 | 0.37 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 42.45 | 6.01 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.